Skip NavigationSkip to Content
Return Return to Search Results

Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model

  1. Author:
    Oshiro, Hiromichi
    Tome, Yasunori
    Kiyuna, Tasuku
    Miyake, Kentaro
    Kawaguchi, Kei
    Higuchi, Takashi
    Miyake, Masuyo
    Zang, Zhiying
    Razmjooei, Sahar
    Barangi, Maryam
    Wangsiricharoen, Sintawat
    Nelson, Scott D
    Li, Yunfeng
    Bouvet, Michael
    Singh,Shree Ram
    Kanaya, Fuminori
    Hoffman, Robert M

  2. Author Address

    AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan., Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Electronic address: yash_toume@hotmail.com., AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA., Department of Pathology, University of California, Los Angeles, CA, USA., Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov., AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.,
    1. Year: 2019
    2. Date: Jun
    3. Epub Date: 2019 04 03
  2. Journal: Tissue & cell
    1. 58
    2. Pages: 17-23
  4. Type of Article: Article
  1. Abstract:

    Follicular dendritic cell sarcoma (FDCS) is a very rare and highly recalcitrant disease. A patient's doxorubicin-resistant FDCS was previously established orthotopically on the right high thigh into the biceps femoris of mice to establish a patient-derived orthotopic xenograft (PDOX) model. The aim of the present manuscript was to identify an effective drug for this recalcitrant tumor. Here, we evaluated the efficacy of temozolomide (TMZ), trabectedin (TRAB) and pazopanib (PAZ) on the FDCS PDOX model. PDOX mouse models were randomized into five groups of eight to nine mice, respectively. Group 1, untreated control with PBS, i.p.; Group 2, treated with doxorubicin (DOX), 2.4?mg/kg, i.p., weekly for 3 weeks; Group 3, treated with PAZ, 50?mg/kg, oral gavage, daily for 3 weeks; Group 4, treated with TMZ, 25?mg/kg, oral gavage, daily for 3 weeks; Group 5, treated with TRAB, 0.15?mg/kg, i.v., weekly for 3 weeks. Body weight and tumor volume were assessed 2 times per week. TMZ arrested the FDCS PDOX model compared to the control group (p?< ?0.05). PAZ and TRAB did not have significant efficacy compared to the control group (p?=?0.99, p?=?0.69 respectively). The PDOX tumor was resistant to DOX (p= 0.99). as was the patient. The present study demonstrates that TMZ is effective for a PDOX model of FDCS established from a patient who failed DOX treatment, further demonstrating the power of PDOX to identify effective therapy including for tumors that failed first line therapy. Published by Elsevier Ltd.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.tice.2019.04.002
  3. PMID: 31133242
  4. PII : S0040-8166(19)30129-6

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at FrederickClose Button

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel